FDA Approves Regeneron's Otarmeni as First Gene Therapy for Genetic Hearing Loss, with the Drugmaker Pledging Free Access in the U.S.
Regeneron's one-time intracochlear gene therapy for OTOF-related deafness cleared the FDA 61 days after BLA filing, the first gene therapy product approved under the Commissioner's National Priority Voucher pilot program.
Overview
The U.S. Food and Drug Administration on April 23, 2026, granted accelerated approval to Regeneron Pharmaceuticals’ Otarmeni (lunsotogene parvec-cwha), making it the first gene therapy ever cleared in the United States for an inherited form of deafness. The decision, announced by the FDA, arrived 61 days after Regeneron filed its biologics license application — a turnaround the agency described as tied for the fastest BLA approval in modern FDA history.
In an unusual move for a one-time genetic medicine, Regeneron said it will provide the therapy at no cost to clinically eligible U.S. patients through a support program called “OnPath with OTARMENI,” though the company acknowledged that out-of-pocket costs for administration of the therapy fall outside its control.
What We Know
The condition and the therapy
Otarmeni is indicated for pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss caused by molecularly confirmed biallelic variants in the OTOF gene, according to the FDA’s press announcement. The condition is rare: NBC News reported that OTOF mutations affect roughly 50 babies born in the United States each year. The mutated gene fails to produce a functional version of otoferlin, a protein that inner-ear hair cells need to relay sound to the auditory nerve.
The therapy is a dual adeno-associated virus (AAV) vector that delivers a working copy of OTOF directly into cochlear hair cells, the FDA explained. It is administered as a single dose per ear via an intracochlear infusion performed under general anesthesia using a syringe and catheter supplied in a dedicated administration kit.
CHORD trial results
Approval rests on the open-label, multicenter Phase 1/2 CHORD trial, which enrolled 20 patients between 10 months and 16 years old, Regeneron’s release said. Ten received unilateral injections and ten received bilateral injections.
The FDA noted that of the 20 evaluable patients, 80 percent experienced improved hearing, an outcome “not expected in the natural history of the disease without intervention.” CNN reported that 16 of the 20 children showed hearing improvements roughly five months after treatment, and that among the 12 participants followed for at least 11 months, five had their hearing essentially restored to normal.
Safety and access
Regeneron disclosed that the most common adverse reactions occurring in at least 5 percent of treated patients included otitis media, vomiting, nausea, dizziness, procedural pain, gait disturbance and nystagmus. Serious surgical risks identified in the label include vertigo, cerebrospinal fluid leak, meningitis and facial nerve paresis.
Otarmeni carries Orphan Drug, Rare Pediatric Disease, Fast Track and Regenerative Medicine Advanced Therapy designations, Regeneron noted. George D. Yancopoulos, M.D., Ph.D., Regeneron’s Board co-Chair, President and Chief Scientific Officer, called the therapy “an unprecedented breakthrough in gene therapy” that has “already proven to be life-changing for many of the children in our clinical trial,” according to the company’s announcement.
Comparison to existing options
Until now, the only intervention available for OTOF-related congenital deafness has been a cochlear implant, NBC News reported. That device restores access to speech and music but reduces the fidelity of the sound, NBC noted, citing Dr. A. Eliot Shearer, an otolaryngologist at Boston Children’s Hospital and a CHORD trial investigator, who told NBC that with gene therapy the improved hearing is “on 24/7 and doesn’t rely on batteries.” The Machine Herald has previously reported on the cochlear-implant landscape, where Envoy Medical’s fully implanted device reached its 12-month endpoint earlier this month.
A new regulatory pathway
Otarmeni is the sixth approval — and the first gene therapy product — granted under the Commissioner’s National Priority Voucher pilot program, the FDA stated. The voucher program is designed to compress review timelines for products that the commissioner deems aligned with national health priorities. The 61-day BLA review for Otarmeni stands in sharp contrast to the standard 10-month review clock for a biologic, illustrating how aggressively the pilot is shortening timelines for a narrow set of submissions.
What We Don’t Know
- Long-term durability. The longest follow-up reported in the CHORD label is roughly 48 weeks. Whether AAV-delivered OTOF expression persists for years, or whether a meaningful share of patients lose hearing gains over time, will require post-approval follow-up. The FDA’s accelerated-approval framework typically requires confirmatory studies to verify clinical benefit.
- How “free” plays out in practice. Regeneron’s pledge applies to the drug itself for clinically eligible U.S. patients. Regeneron’s release explicitly cautions that “out-of-pocket costs for administration of this free therapy” fall outside the company’s control, leaving open questions about insurance coverage and total cost for families.
- Patient identification. OTOF deafness is genetically defined and not always captured by current newborn-hearing screening protocols, which typically detect hearing loss but do not sequence the underlying gene. Reaching the estimated 50 newborns per year identified by NBC News will depend on how quickly genetic testing is integrated into pediatric audiology workflows.
- Implications for the broader voucher pipeline. Otarmeni is the first gene therapy cleared under the National Priority Voucher pathway. Whether the same compressed timeline can be applied responsibly to gene therapies addressing larger or more heterogeneous patient populations remains to be tested.
Why It Matters
The approval marks the first time a U.S.-licensed product directly corrects the genetic root cause of an inherited form of deafness, expanding the reach of single-administration AAV gene therapies beyond eye and blood diseases into the auditory system. It also stress-tests two coupled experiments at once: an unusually fast regulatory pathway designed to move priority products through review in months rather than years, and a sponsor-funded free-drug model intended to make a one-time genetic medicine accessible without the multimillion-dollar list price that has defined recent gene therapies. Whether either model is durable will be visible long before Otarmeni’s label-mandated confirmatory data arrive.